TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
Details
Publication Year 2023-04-05,Volume 15,Issue #690,Page eabk1900
Journal Title
Science Translational Medicine
Publication Type
Research article
Abstract
Patients who receive chimeric antigen receptor (CAR)-T cells that are enriched in memory T cells exhibit better disease control as a result of increased expansion and persistence of the CAR-T cells. Human memory T cells include stem-like CD8(+) memory T cell progenitors that can become either functional stem-like T (T(STEM)) cells or dysfunctional T progenitor exhausted (T(PEX)) cells. To that end, we demonstrated that T(STEM) cells were less abundant in infused CAR-T cell products in a phase 1 clinical trial testing Lewis Y-CAR-T cells (NCT03851146), and the infused CAR-T cells displayed poor persistence in patients. To address this issue, we developed a production protocol to generate T(STEM)-like CAR-T cells enriched for expression of genes in cell replication pathways. Compared with conventional CAR-T cells, T(STEM)-like CAR-T cells had enhanced proliferative capacity and increased cytokine secretion after CAR stimulation, including after chronic CAR stimulation in vitro. These responses were dependent on the presence of CD4(+) T cells during T(STEM)-like CAR-T cell production. Adoptive transfer of T(STEM)-like CAR-T cells induced better control of established tumors and resistance to tumor rechallenge in preclinical models. These more favorable outcomes were associated with increased persistence of T(STEM)-like CAR-T cells and an increased memory T cell pool. Last, T(STEM)-like CAR-T cells and anti-programmed cell death protein 1 (PD-1) treatment eradicated established tumors, and this was associated with increased tumor-infiltrating CD8(+)CAR(+) T cells producing interferon-gamma. In conclusion, our CAR-T cell protocol generated T(STEM)-like CAR-T cells with enhanced therapeutic efficacy, resulting in increased proliferative capacity and persistence in vivo.
Publisher
American Association for the Advancement of Science
Keywords
Humans; *Immunotherapy, Adoptive/methods; *Neoplasms; T-Lymphocytes; Cytokines/metabolism; Stem Cells/metabolism; Receptors, Antigen, T-Cell/metabolism
Department(s)
Laboratory Research; Medical Oncology
PubMed ID
37018415
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-08-03 07:58:24
Last Modified: 2023-08-03 08:01:33

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙